These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 17875119)

  • 1. Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people.
    Hu XP; Xu JM; Hu YM; Mei Q; Xu XH
    J Clin Pharm Ther; 2007 Oct; 32(5):517-24. PubMed ID: 17875119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects.
    Hu YM; Xu JM; Mei Q; Xu XH; Xu SY
    Acta Pharmacol Sin; 2005 Mar; 26(3):384-8. PubMed ID: 15715938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic and kinetic effect of rabeprazole on serum gastrin level in relation to CYP2C19 polymorphism in Chinese Hans.
    Hu YM; Mei Q; Xu XH; Hu XP; Hu NZ; Xu JM
    World J Gastroenterol; 2006 Aug; 12(29):4750-3. PubMed ID: 16937451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of CYP2C19 on the relationship between pharmacokinetics and intragastric pH of omeprazole administered by successive intravenous infusions in Chinese healthy volunteers.
    Wang Y; Zhang H; Meng L; Wang M; Yuan H; Ou N; Zhang H; Li Z; Shi R
    Eur J Clin Pharmacol; 2010 Jun; 66(6):563-9. PubMed ID: 20414645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans.
    Furuta T; Ohashi K; Kosuge K; Zhao XJ; Takashima M; Kimura M; Nishimoto M; Hanai H; Kaneko E; Ishizaki T
    Clin Pharmacol Ther; 1999 May; 65(5):552-61. PubMed ID: 10340921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism.
    Sagar M; Tybring G; Dahl ML; Bertilsson L; Seensalu R
    Gastroenterology; 2000 Sep; 119(3):670-6. PubMed ID: 10982760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19.
    Furuta T; Shirai N; Xiao F; Ohashi K; Ishizaki T
    Clin Pharmacol Ther; 2001 Nov; 70(5):484-92. PubMed ID: 11719736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype.
    Qiao HL; Hu YR; Tian X; Jia LJ; Gao N; Zhang LR; Guo YZ
    Eur J Clin Pharmacol; 2006 Feb; 62(2):107-12. PubMed ID: 16402242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: which is suitable for on-demand therapy?
    Inamori M; Togawa J; Takahashi K; Yoneda M; Fujisawa N; Iwasaki T; Ozawa Y; Kikuchi T; Muramatsu K; Chiguchi G; Matsumoto S; Kawamura H; Abe Y; Kirikoshi H; Kobayashi N; Sakaguchi T; Takamura T; Nakajima A; Ueno N; Sekihara H
    J Gastroenterol Hepatol; 2003 Sep; 18(9):1034-8. PubMed ID: 12911659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole.
    Adachi K; Katsube T; Kawamura A; Takashima T; Yuki M; Amano K; Ishihara S; Fukuda R; Watanabe M; Kinoshita Y
    Aliment Pharmacol Ther; 2000 Oct; 14(10):1259-66. PubMed ID: 11012469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes.
    Hu YR; Qiao HL; Kan QC
    Acta Pharmacol Sin; 2004 Aug; 25(8):986-90. PubMed ID: 15301728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability.
    Yin OQ; Tomlinson B; Chow AH; Waye MM; Chow MS
    J Clin Pharmacol; 2004 Jun; 44(6):582-9. PubMed ID: 15145965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status.
    Sugimoto M; Furuta T; Shirai N; Kajimura M; Hishida A; Sakurai M; Ohashi K; Ishizaki T
    Clin Pharmacol Ther; 2004 Oct; 76(4):290-301. PubMed ID: 15470328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes.
    Horai Y; Kimura M; Furuie H; Matsuguma K; Irie S; Koga Y; Nagahama T; Murakami M; Matsui T; Yao T; Urae A; Ishizaki T
    Aliment Pharmacol Ther; 2001 Jun; 15(6):793-803. PubMed ID: 11380317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2C19 genotype related effect of omeprazole on intragastric pH and antimicrobial stability.
    Kita T; Tanigawara Y; Aoyama N; Hohda T; Saijoh Y; Komada F; Sakaeda T; Okumura K; Sakai T; Kasuga M
    Pharm Res; 2001 May; 18(5):615-21. PubMed ID: 11465416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers.
    Aoyama N; Tanigawara Y; Kita T; Sakai T; Shirakawa K; Shirasaka D; Kodama F; Okumura K; Kasuga M
    J Gastroenterol; 1999; 34 Suppl 11():80-3. PubMed ID: 10616772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans.
    Furuta T; Ohashi K; Kobayashi K; Iida I; Yoshida H; Shirai N; Takashima M; Kosuge K; Hanai H; Chiba K; Ishizaki T; Kaneko E
    Clin Pharmacol Ther; 1999 Sep; 66(3):265-74. PubMed ID: 10511062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Which has superior acid-suppressive effect, 10 mg omeprazole once daily or 20 mg famotidine twice daily? Effects of single or repeated administration in Japanese Helicobacter pylori-negative CYP2C19 extensive metabolizers.
    Shimatani T; Inoue M; Kuroiwa T; Moriwaki M; Xu J; Ikawa K; Morikawa N; Tazuma S
    Dig Dis Sci; 2007 Feb; 52(2):390-5. PubMed ID: 17211705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
    Saitoh T; Fukushima Y; Otsuka H; Hirakawa J; Mori H; Asano T; Ishikawa T; Katsube T; Ogawa K; Ohkawa S
    Aliment Pharmacol Ther; 2002 Oct; 16(10):1811-7. PubMed ID: 12269976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations.
    Uno T; Niioka T; Hayakari M; Yasui-Furukori N; Sugawara K; Tateishi T
    Eur J Clin Pharmacol; 2007 Feb; 63(2):143-9. PubMed ID: 17203292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.